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Background: This update outlines changes to the MObile Technology for Improved Family Planning study
statistical analysis plan and plans for long-term follow-up. These changes result from obtaining additional funding
and the decision to restrict the primary analysis to participants with available follow-up data. The changes were
agreed prior to finalising the statistical analysis plan and sealing the dataset.
Methods/design: The primary analysis will now be restricted to subjects with data on the primary outcome at
4-month follow-up. The extreme-case scenario, where all those lost to follow-up are counted as non-adherent, will
be used in a sensitivity analysis. In addition to the secondary outcomes outlined in the protocol, we will assess the
effect of the intervention on long-acting contraception (implant, intra-uterine device and permanent methods).
To assess the long-term effect of the intervention, we plan to conduct additional 12-month follow-up by telephone
self-report for all the primary and secondary outcomes used at 4 months. All participants provided informed consent
for this additional follow-up when recruited to the trial. Outcome measures and analysis at 12 months will be similar to
those at the 4-month follow-up. The primary outcomes of the trial will be the use of an effective modern contraceptive
method at 4 months and at 12 months post-abortion. Secondary outcomes will include long-acting contraception use,
self-reported pregnancy, repeat abortion and contraception use over the 12-month post-abortion period.
Discussion: Restricting the primary analysis to those with follow-up data is the standard approach for trial analysis and
will facilitate comparison with other trials of interventions designed to increase contraception uptake or use. Undertaking
12-month trial follow-up will allow us to evaluate the long-term effect of the intervention.
Trial registration: ClinicalTrials.gov NCT01823861.
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Background
This update outlines changes to the MObile Technology
for Improved Family Planning (MOTIF) study statistical
analysis plan and plans for long-term follow-up. These
changes, subsequent to the publication of the protocol
in Trials [1], result from discussions within the research
team, recommendations from one author’s (CS) PhD ex-
aminers, and procurement of additional funding to con-
duct further follow-up. The changes were agreed and we
informed Trials on 12 June 2014 prior to finalising the
statistical analysis plan and sealing the dataset.* Correspondence: christopher.smith@lshtm.ac.uk
1Department of Population Health, London School of Hygiene and Tropical
Medicine, London, UK
Full list of author information is available at the end of the article
© 2014 Smith et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Changes to 4-month analysis
The primary analysis will be restricted to participants
with available follow-up data. This is a more common
approach to trial analysis and is standard in trials of in-
terventions designed to increase contraception use [2-4].
This change will therefore facilitate comparison of our
results with other studies. The primary outcome remains
the same: use of an effective modern method of contra-
ception at 4 months post-abortion. For the primary ana-
lysis, we originally planned to consider all participants
lost to follow-up as non-users of contraception. This is
clearly an extreme-case scenario and is likely to under-
estimate contraceptive rates, as it is unlikely that all sub-
jects lost to follow-up will be non-users. We now consider
that this would be more appropriate for a sensitivity ana-
lysis. While the subset of subjects with follow-up datatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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across arms should provide an internally valid comparison,
providing follow-up rates are similar in the intervention
and control arms.
In addition to the secondary outcomes outlined in the
protocol, we will assess the effect of the intervention on
long-acting contraception. Marie Stopes International
Cambodia considers implant, intra-uterine device and
permanent methods to be long-acting contraception. We
anticipate that this additional secondary analysis will be
of value to family planning service providers. The re-
searchers conducting the data analysis will be blind to
treatment allocation. A second independent researcher
will check the analyses.
Long-term trial follow-up
At recruitment, participants were given the option to
consent for additional self-report follow-up of primary
and secondary outcomes at 12 and 24 months, subject
to the trial’s obtaining additional funding. All 500 trial
participants provided consent for this potential additional
follow-up. Subsequently CS obtained a Medical Research
Council Population Scientist Fellowship, which included
some funds for long-term MOTIF trial follow-up.
We obtained self-report follow-up data on 86.2% of
participants at 4 months. Six participants withdrew from
the study. This follow-up was conducted by two research
assistants over a 5-month period.
To assess the long-term effect of the intervention, we
plan to conduct 12-month trial follow-up on the remaining
492 trial participants, commencing July 2014. The follow-
up questionnaire will be similar to that used at 4 months.
We will collect information on current contraceptive use,
repeat pregnancy or abortion, and contraception use over
the 12-month post-abortion period. In addition, we will
ask participants using contraception where they obtained
it. We anticipate that it will take several months to conduct
12-month follow-up. Having achieved 86.2% follow-up at
4 months, we anticipate increased attrition at subse-
quent follow-up. Owing to limited resources, we will not
complete follow-up at 24 months.
Outcome measures and analysis will be similar to
those at the 4-month follow-up. The primary outcome at
the 12-month follow-up will be use of an effective modern
contraceptive method at 12-months post-abortion. This
will be considered a second primary outcome, in addition
to effective modern contraceptive use at 4 months.
Secondary outcomes include long-acting contraception
use, self-reported pregnancy, repeat abortion, and contra-
ception use over the 12-month post-abortion period
(to estimate the point prevalence of contraception use at
any given time and of contraceptive discontinuation rates).
For the primary outcomes and for secondary outcomes
with binary outcome measures we will estimate risk ratioswith 95% confidence intervals and give a two-sided P value
for statistical significance using the chi-squared test.
We will perform Kaplan-Meier survival analysis to assess
contraceptive discontinuation rates.
We will perform sub-group and sensitivity analysis as
per the 4-month analysis. For sub-group analysis, we will
assess whether the effect of the intervention varies accord-
ing to age, urban versus rural residence, level of education
and socioeconomic status. We will use the chi-squared test
for heterogeneity at a 5% level of significance. If statistically
significant overall heterogeneity is identified, relative risks
and 99% confidence intervals will be estimated. Sensitivity
analysis will include counting those lost to follow-up as
non-users, per-protocol analysis, and analysis of clustering
among participants from each clinic, as for the 4-month
follow-up.
Ethics
Ethical approval for this additional follow-up has been
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Conclusion
Restricting the primary analysis to those with follow-up
data is the standard approach for trial analysis and will
facilitate comparison with other trials of interventions de-
signed to increase contraception uptake or use. Undertak-
ing 12-month trial follow-up will allow us to evaluate the
long-term effect of the intervention.
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